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Abstract  
Background: Temperature-sensitive liposomes (TSL) in combination with hyperthermia (HT) 
exposure have emerged as a potentially attractive option to achieve therapeutic drug 
concentration at targeted tumour site while reducing adverse side effects associated with 
systemic administration of anticancer drugs. The aim of this study is to elucidate the interplay 
among different kinetic steps by means of computational modelling.   
Methods: A multi-compartment model for TSL-mediated delivery of doxorubicin (DOX) is 
developed, which incorporates descriptions of the pharmacokinetics of TSL and DOX, and 
their accumulation in tumour tissue following intravascular triggered release. By examining 
dynamic interactions among TSL properties, tumour physiological properties and treatment 
regimen, peak intracellular DOX concentration is predicted for continuous and pulse HT 
exposures.  
Results: Drug release rate from TSL has a saturable effect on peak intracellular drug 
concentration, and no further gain could be achieved for release rates greater than 0.1018 s
-1
. 
A similar effect has also been found for heating duration, such that for a given bolus injection, 
peak intracellular drug concentration reaches its maximum and then levels off after HT 
duration of 2 hours. These results suggest that both TSL release rate and HT duration can be 
optimised in accordance with other parameters, e.g. clearance rate of TSL and administration 
mode, in order to achieve a desirable level of intracellular drug concentration. However, 
prolonged heating is not effective for resistant tumour cells with overexpression of ABC 
(ATP-binding cassette) transporter proteins. 
Conclusions: The results obtained in this study can be used to guide the design and 
optimisation of TSL parameters and treatment regimens. 
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1. Introduction 
Liposomal encapsulation of anticancer agents, as a drug delivery system, has been developed 
to overcome the limitations of conventional free drug treatment, by reducing systemic 
cytotoxicity, prolonging plasma half-life and passively targeting tumour sites as a result of 
enhanced permeability and retention (EPR) effect [1]. Liposomal formulations of doxorubicin 
(DOX) (e.g., Doxil
®
) have been approved for clinical use in the treatment of ovarian cancer; 
however, their clinical efficacy is limited by insufficient local DOX concentration due to 
slow release kinetics. Therefore, considerable effort has been made on designing liposomes 
that are capable of targeting tumour actively and releasing encapsulated agents rapidly in 
response to specific stimulus, temperature-sensitive liposomes (TSL) being one of these [2].  
 
As a localized therapy, TSL are expected to remain stable at body temperature but can be 
triggered to release the encapsulated drug rapidly (within seconds to minutes) when they are 
heated to a designated temperature at the tumour site [3, 4]. In addition, local hyperthermia 
(HT) alone has been shown to improve accumulation of TSL in solid tumour by accentuating 
the leakiness of tumour vasculature [5]. Among several HT applicators, such as 
radiofrequency, microwave, and lasers, high intensity focused ultrasound (HIFU) has a 
distinct advantage due to its non-invasive and controllable nature [2]. More importantly, 
when combined with magnetic resonance imaging (MRI), MRI guided HIFU can offer real-
time temperature monitoring with a feedback control, which is critical to TSL-based delivery 
systems activated by HIFU [6]. 
 
The application of TSL in conjunction with local HT has shown promising prospect both in 
preclinical studies and in clinical trials. Current TSL research is mainly focused on 
formulation design, especially with regard to release kinetics in response to HT exposure. 
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However, among the multiple transport steps in a drug delivery process, drug release is an 
intermediate step that is preceded by the upstream transport (systemic circulation) and 
followed by the downstream transport (transvascular/interstitial and eventually intracellular 
transport). Furthermore, the target output, i.e. peak intracellular drug concentration, is not 
only influenced by interactions among these multiple transport steps, but also by the 
characteristics of HT applicators. It is a formidable task to measure the entire range of drug 
concentrations as well as a large amount of parameters experimentally. On the other hand, it 
is beyond our intuitive understanding to appreciate temporal variations of drug concentrations, 
and their dependence on the constituent parameters. For these reasons, an in silico model can 
play a key role in gaining insights into the transport processes of TSL in combination with 
their response to HT exposure. In silico experiments can be carried out as a precursor and 
supplement to experimental studies, in order to provide guideline for further design and 
optimisation of TSL drug delivery systems and their combination with various HT applicators. 
 
Based on the concept of multi-compartment model, a number of mathematical models [7-12] 
have been developed to describe biological transport processes involved in stealth liposomes 
and TSL. These models have provided various levels of insight into the delivery of liposomal 
carriers, bioavailability in the tumour tissue, and its correlation to cytotoxic effect. In 
particular, mathematical models of TSL delivery require tempo-spatial profiles of 
temperature as input (stimulus) to account for temperature-dependent release kinetics. This 
can be achieved by assuming a homogeneous distribution of desired temperature in the entire 
tumour region [10], or by coupling with a bio-heat transfer model. In their recently published 
computational studies, Gasselhuber et al. [9, 13] predicted distributions of temperature and 
drug concentration in response to two different heating modalities, and their numerical results 
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showed a qualitative agreement with preliminary in vivo data. However, a systematic study 
with a thorough sensitivity analysis of the input parameters is lacking.  
 
Employing a multi-compartment model together with the assumption of a homogeneous 
temperature distribution, the present study aims to provide clear-cut information on the 
interplays among multiple transport steps involved in the the delivery of TSL-encapsulated 
doxorubicin (DOX). Compared to the mathematical models employed by Gasselhuber et al. 
[9, 10, 13], an additional compartment for tumour plasma is introduced in the present study, 
which allows distinction of TSL in systemic plasma from those in tumour plasma. A 
systematic study is then performed by contrasting and comparing numerical results in 
response to continuous and pulse temperature stimuli. A sensitivity analysis is carried out to 
determine which input parameters have the greatest influence on the peak intracellular drug 
concentration (𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 ), and how these parameters affect 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  under continuous and pulse 
HT exposure.  
 
2. Methods 
A multi-compartment model (Figure 1) is adopted to describe the transport of liposomes and 
unencapsulated drug following intravenous injection of drug-loaded TSL. The model consists 
of three high level compartments: systemic plasma, lumped tissue and tumour. The tumour 
compartment is further divided into three sub-compartments, namely tumour plasma, tumour 
extravascular extracellular space (EES) and tumour intracellular space. There are eight 
variables representing drug concentrations in either liposomal or free form in different 
compartments and the mass conservation equation for each variable incorporates kinetic 
transfer and reaction processes. A general assumption underlying all compartmental models 
is homogeneity in each compartment, i.e. a well-mixed system with a uniform temperature 
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and uniform tumour cell density. In the equations described in the subsequent sections, drug 
concentrations are expressed in micrograms (μg) per mm3 of the volume of their 
corresponding compartment.  
 
2.1 Pharmacokinetics of TSL: systemic plasma compartment 
Pharmacokinetics of TSL is described by one compartment, i.e. systemic plasma. The volume 
of the central compartment is set to the volume of systemic plasma (𝑉𝑃
𝐵), which implies that 
the latter is consistent with the volume of TSL distribution [7]. Following an intravenous 
injection, the concentration of TSL in systemic plasma compartment (𝑐𝑃_𝐿𝑖𝑝
𝐵 ) is determined by:  
𝑉𝑃
𝐵 𝑑𝑐𝑃_𝐿𝑖𝑝
𝐵
𝑑𝑡
=  𝐷 𝑇𝑑
⁄ ∗ 𝐻(𝑇𝑑 − 𝑡) − 𝑘𝑒_𝐿𝑖𝑝𝑐𝑃_𝐿𝑖𝑝
𝐵 𝑉𝑃
𝐵 − 𝑘𝑟37𝑐𝑃_𝐿𝑖𝑝
𝐵 𝑉𝑃
𝐵 + 𝐹𝑃𝑉
𝑇 𝑉𝑃
𝑇𝑐𝑃_𝐿𝑖𝑝
𝑇 −
𝐹𝑃𝑉
𝑇 𝑉𝑃
𝑇𝑐𝑃_𝐿𝑖𝑝
𝐵                                                                                                              1 
where D is the dose of TSL, and 𝑇𝑑 is the infusion duration. The Heaviside term 𝐻(𝑇𝑑 − 𝑡) 
describes a constant infusion of TSL during the period of t= 0 to 𝑇𝑑 only. Perfect mixing of 
TSL is assumed within systemic plasma. TSL are eliminated via body clearance at rate 𝑘𝑒_𝐿𝑖𝑝. 
A first order kinetics with a rate constant of 𝑘𝑟37 is used to describe the release of DOX  in 
systemic plasma due to instability of TSL at body temperature [10]. 
For bolus injection, Equation 1 is reduced to: 
𝑽𝑷
𝑩 𝒅𝒄𝑷_𝑳𝒊𝒑
𝑩
𝒅𝒕
= −𝒌𝒆_𝑳𝒊𝒑𝒄𝑷_𝑳𝒊𝒑
𝑩 𝑽𝑷
𝑩 − 𝒌𝒓𝟑𝟕𝒄𝑷_𝑳𝒊𝒑
𝑩 𝑽𝑷
𝑩 + 𝑭𝑷𝑽
𝑻 𝑽𝑷
𝑻𝒄𝑷_𝑳𝒊𝒑
𝑻 − 𝑭𝑷𝑽
𝑻 𝑽𝑷
𝑻𝒄𝑷_𝑳𝒊𝒑
𝑩  1A 
 
2.2 Pharmacokinetics of free DOX: systemic plasma & tissue compartments 
Pharmacokinetics of free DOX is described by a two-compartment model, with one common 
systemic plasma compartment shared with TSL and the other representing lumped body 
tissues with significant drug uptake. Free DOX is present in systemic plasma compartment 
due to instability of TSLs at body temperature and is cleared from the body at rate 𝑘𝑒. 
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Exchange of free DOX between systemic plasma compartment and tissue compartment is 
described by a bidirectional linear kinetics at transfer rate 𝑘𝑃 and 𝑘𝑡, respectively.   
𝑽𝑷
𝑩 𝒅𝒄𝑷
𝑩
𝒅𝒕
= 𝒌𝒓𝟑𝟕𝒄𝑷_𝑳𝒊𝒑
𝑩 𝑽𝑷
𝑩 − 𝒌𝒆𝒄𝑷
𝑩𝑽𝑷
𝑩 − 𝒌𝑷𝒄𝑷
𝑩𝑽𝑷
𝑩 + 𝒌𝒕𝒄𝒕
𝑩𝑽𝒕
𝑩 + 𝑭𝑷𝑽
𝑻 𝑽𝑷
𝑻𝒄𝑷
𝑻 − 𝑭𝑷𝑽
𝑻 𝑽𝑷
𝑻𝒄𝑷
𝑩 2 
 
The concentration of free DOX in tissue compartment (𝑐𝑡
𝐵) is described by:  
𝑽𝒕
𝑩 𝒅𝒄𝒕
𝑩
𝒅𝒕
= 𝒌𝑷𝒄𝑷
𝑩𝑽𝑷
𝑩 − 𝒌𝒕𝒄𝒕
𝑩𝑽𝒕
𝑩
                                                                                                                   3 
 
2.3 Tumour deposition 
Tumour plasma compartment 
Tumour plasma compartment is linked to systemic plasma compartment via blood perfusion, 
which accounts for convective transport (𝐹𝑃𝑉
𝑇 𝑉𝑃
𝑇𝑐) of TSL and free DOX between blood and 
tumour. Here 𝐹𝑃𝑉
𝑇  is defined as plasma flow per tumour plasma volume. When tumour is 
heated to a designated temperature (e.g. 42°C), rapid release of DOX from TSL is triggered 
in tumour plasma, which is assumed to follow a linear kinetics at rate 𝑘𝑟42. After heating is 
ceased, the release rate is reduced to the rate at body temperature (𝑘𝑟37). The concentration of 
TSL in tumour plasma compartment (𝑐𝑃_𝐿𝑖𝑝
𝑇 ) is described as 
𝑽𝑷
𝑻 𝒅𝒄𝑷_𝑳𝒊𝒑
𝑻
𝒅𝒕
= 𝑭𝑷𝑽
𝑻 𝑽𝑷
𝑻𝒄𝑷_𝑳𝒊𝒑
𝑩 − 𝑭𝑷𝑽
𝑻 𝑽𝑷
𝑻𝒄𝑷_𝑳𝒊𝒑
𝑻 − 𝑯(𝑻𝒉 − 𝒕) ∗ 𝒌𝒓𝟒𝟐𝒄𝑷𝑳𝒊𝒑
𝑻 𝑽𝑷
𝑻 − 𝑯(𝒕 − 𝑻𝒉) ∗
𝒌𝒓𝟑𝟕𝒄𝑷𝑳𝒊𝒑
𝑻 𝑽𝑷
𝑻
                                                                                                                                                   4 
Heaviside term 𝐻(𝑇ℎ − 𝑡) represents HT exposure during the period of t = 0 to Th. 
Unencapsulated DOX in response to HT in tumour plasma provides the driving force for 
transvascular drug transport into tumour EES. Diffusion is the dominant transport mechanism 
for transvascular drug transport as convection is negligible in tumours due to elevated 
interstitial fluid pressure. The diffusive flux across the interface between tumour plasma 
volume and tumour EES is determined by the product of vascular permeability and surface 
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area (𝑃𝑆𝑡) as well as the concentration difference of free DOX between tumour plasma (𝑐𝑃
𝑇) 
and tumour EES (𝑐𝑒
𝑇). Transvascular transport of TSL to tumour EES is assumed to be 
negligible for two reasons: (1) for intravascular triggered release, which is the mode of TSL 
release examined in the current study, release of DOX is triggered before extravasation of 
TSL from tumour plasma to tumour EES; (2) vascular permeability of TSL is several orders 
of magnitude lower than that of free DOX.  
𝑽𝑷
𝑻 𝒅𝒄𝑷
𝑻
𝒅𝒕
= 𝑭𝑷𝑽
𝑻 𝑽𝑷
𝑻𝒄𝑷
𝑩 − 𝑭𝑷𝑽
𝑻 𝑽𝑷
𝑻𝒄𝑷
𝑻 + 𝑯(𝑻𝒉 − 𝒕) ∗ 𝒌𝒓𝟒𝟐𝒄𝑷𝑳𝒊𝒑
𝑻 𝑽𝑷
𝑻 + 𝑯(𝒕 − 𝑻𝒉) ∗ 𝒌𝒓𝟑𝟕𝒄𝑷𝑳𝒊𝒑
𝑻 𝑽𝑷
𝑻 −
𝑽𝑻𝑷𝑺𝒕(𝒄𝑷
𝑻 − 𝒄𝒆
𝑻)                                                                                                                                                  5 
 
Tumour EES 
Upon entering tumour EES, free drugs are consumed by tumour cells (denoted by 𝑑𝑐𝑉
𝑇, the 
product of tumour cell density 𝑑𝑐 and tumour volume 𝑉
𝑇). Two different intracellular uptake 
mechanisms are accounted for: passive diffusive transport and active transport modeled by 
Michaelis-Menten kinetics. On the other hand, intracellular drugs can be pumped out of cells, 
most likely by membrane transporter proteins (e.g. P-glycoprotein), which could be 
significant in resistant tumour cells associated with overexpression of transporter proteins. In 
addition, binding of free drugs to interstitial proteins (e.g. albumin) should be accounted for. 
At binding rate 𝑘𝑏 and reversible disassociate rate 𝑘𝑑, the equation for free drug 
concentration in tumour EES can be expressed as: 
𝑽𝒆
𝑻 𝒅𝒄𝒆
𝑻
𝒅𝒕
= 𝑽𝑻𝑷𝑺𝒕(𝒄𝑷
𝑻 − 𝒄𝒆
𝑻) − 𝒅𝒄𝑽
𝑻 (𝒌𝟏𝒄𝒊𝒄𝒆
𝑻 +
𝑽𝒎𝒂𝒙_𝒊𝒏𝒄𝒆
𝑻
𝒄𝒆
𝑻+𝑲𝒆𝒗𝒆
𝑻 −
𝑽𝒎𝒂𝒙_𝒐𝒖𝒕𝒄𝒊
𝑻
𝒄𝒊
𝑻+𝑲𝒊
) − 𝒌𝒃𝒄𝒆
𝑻𝑽𝒆
𝑻 + 𝒌𝒅𝒄𝒃
𝑻𝑽𝒆
𝑻 
                                                                                                                                                                           6 
where the concentration of bound drug in tumour EES is described by: 
𝒅𝒄𝒃
𝑻
𝒅𝒕
= 𝒌𝒃𝒄𝒆
𝑻 − 𝒌𝒅𝒄𝒃
𝑻                                                                                                         7 
10 
 
 
Tumour intracellular space 
As described above, drug concentration in intracellular space (𝑐𝑖
𝑇) is governed by a 
bidirectional transport across the cell membrane: 
𝑽𝒊
𝑻 𝒅𝒄𝒊
𝑻
𝒅𝒕
= 𝒅𝒄𝑽
𝑻 (𝒌𝟏𝒄𝒊𝒄𝒆
𝑻 +
𝑽𝒎𝒂𝒙_𝒊𝒏𝒄𝒆
𝑻
𝒄𝒆
𝑻+𝑲𝒆𝒗𝒆
𝑻 −
𝑽𝒎𝒂𝒙_𝒐𝒖𝒕𝒄𝒊
𝑻
𝒄𝒊
𝑻+𝑲𝒊
)                                                                              8 
 
The system of ordinary differential equations was solved by using Ode15s implemented in 
Matlab. In all simulations unless otherwise stated, TSL are administrated intravenously by 
bolus injection at a dose of 0.7 mg/kg body weight (assuming an average human weight of 70 
kg). HT exposure is applied simultaneously with TSL administration and is assumed to result 
in a desired temperature at the target site instantly. Initial concentrations of all drugs are set to 
be zero except that of TSL in systemic plasma where 𝑐𝑃_𝐿𝑖𝑝
𝐵 (𝑡 = 0) = 𝐷
𝑉𝑃
𝐵⁄ .  
 
2.4 Parameterization  
Model parameters used in the current study can be broadly classified into four categories: 
pharmacokinetics, drug release kinetics, tumour physiology, and cell related parameters. 
Since DOX is a commonly studied agent, values of parameters describing DOX 
pharmacokinetics, transport and uptake are directly adopted from the literature. For TSL drug 
carriers, their release kinetics and pharmacokinetics vary significantly according to their 
formulation. TSL release kinetics reported by Hossann et al [14] was adopted as baseline 
values in the present study, with estimated release rates 
31009.5   s-1 and 5100.1   s-1 at HT 
and physiological temperatures, respectively. Ultra-fast release kinetics has been reported in 
Thermodox
®
 (a commercially available TSL, Celsion, Columbia, MD) with a release rate up 
to 0.3 s
-1
. In addition, tumour physiological properties are highly heterogeneous even in the 
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same tumour, not to mention various tumour types. Therefore, simulations were carried out 
with baseline values first, which were extracted from the literature (Table 1). This was 
followed by a thorough sensitivity analysis to evaluate the relative importance of multiple 
kinetic transport processes. Further details about the ranges of parameters adopted in the 
sensitivity analysis are described later in the Results section. 
 
3. Results 
A systematic investigation of TSL delivery combined with HT was performed. Compared to 
conventional stealth liposomes, predicting the intracellular drug concentration with TSL-
mediated delivery is more complicated as the system is controlled not only by drug signal 
(TSL injection) but also by hyperthermia exposure; the latter can be achieved through 
continuous or pulse heating. In order to focus on providing essential insight into the interplay 
between biological and biochemical processes involved, simulation results corresponding to 
continuous heating are presented first. The effects of pulse heating are then evaluated by 
comparing simulation results performed under different heating schemes.  
 
3.1 Basic model dynamics: time-course of drug concentration  
As shown in Figure 2(a), the concentration profiles of TSL in systemic plasma compartment 
𝑐𝑃_𝐿𝑖𝑝
𝐵  and TSL in tumour plasma compartment 𝑐𝑃_𝐿𝑖𝑝
𝑇  are almost identical, following a 
gradual decline with time. TSL are transported to tumour plasma compartment at sufficiently 
high concentration via blood perfusion. Upon arrival in tumour plasma, rapid release of DOX 
is triggered in response to local HT, which gives rise to a sharp increase in DOX 
concentration in tumour plasma compartment (𝑐𝑃
𝑇). This is followed by a continuous 
reduction in 𝑐𝑃
𝑇, since free DOX is simultaneously removed by the competing kinetic 
transport steps, i.e. perfusion back to systemic plasma and extravasation into tumour EES. As 
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the amount of DOX released from TSL at body temperature is trivial, DOX concentration in 
systemic plasma (𝑐𝑃
𝐵) displays a similar trend to 𝑐𝑃
𝑇 . 
 
Shown in Figure 2(b) are profiles of drug concentrations in tumour compartment. It can be 
seen that the concentration of free DOX in tumour EES (𝑐𝑒
𝑇) reaches its peak before falling 
off gradually. Taking a closer look at the transport steps in tumour EES, 𝑐𝑒
𝑇 is regulated by 
different processes: (1) influx driven by unencapsulated DOX triggered by HT in tumour 
plasma; (2) favourable binding kinetics with nearly 3 times more DOX in bound form (𝑐𝑏
𝑇) 
than in free form (𝑐𝑒
𝑇); (3) effective outflow to tumour intracellular space. Of note, the 
extravasation flux gradually decreases due to diminished concentration difference between 𝑐𝑃
𝑇 
and 𝑐𝑒
𝑇, which cannot overcome counteracting processes. Very high intracellular DOX 
concentration (𝑐𝑖
𝑇) is observed which peaks at around t=130 min, when the profiles of 𝑐𝑃
𝑇 and 
𝑐𝑒
𝑇 intersect. After the peak, 𝑐𝑒
𝑇 is higher than 𝑐𝑃
𝑇, resulting in a reverse concentration gradient 
which drives free DOX in tumour EES to diffuse back to tumour plasma. As a consequence, 
the net flow of DOX in intracellular space becomes efflux-dominant, leading to a reduction in 
𝑐𝑖
𝑇. 
 
Following the analysis of continuous HT exposure, it is more natural to understand how drug 
concentrations evolve over time under pulse HT exposure. Results shown in Figure 3 reveal 
the time-course of all drug concentrations in the baseline case, with 60 min HT exposure at 
42°C. Comparisons with results in Figure 2 show that sudden changes in drug concentrations 
occur at cessation of heating (t=60min), which causes a dramatic reduction in the release rate 
of DOX from TSL. Of note, 𝑐𝑃
𝑇 falls below 𝑐𝑒
𝑇 immediately after termination of heating, 
which drives a series of reverse transport, from tumour intracellular space to tumour EES, 
then back to tumour plasma. Although a similar trend is observed under continuous HT, in 
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which case the process is regulated by the interplay between different kinetic transport steps, 
the reverse transport observed under pulse HT is triggered by termination of heating. 
Comparisons of results in Figure 2 and Figure 3 suggest that: (1) Peak intracellular drug 
concentration is reached at approximately 120 min under continuous heating; and (2) Peak 
intracellular drug concentration is higher under continuous heating than 60 min pulse heating.  
 
3.2 Sensitivity analysis 
Among all drug concentrations, peak intracellular drug concentration 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  is the variable of 
primary interest, as it has been found to correlate with tumour cell survival [11, 15, 16]. 
Using the in silico model described here, a local sensitivity analysis is performed to evaluate 
the relative change in 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  with respect to the baseline case when each tested parameter is 
increased by 10%. Results for both continuous HT and 60 min pulse HT are obtained and 
Figure 4 shows that: (1) Parameters governing pharmacokinetics of unencapsulated DOX 
(𝑘𝑝, 𝑘𝑡 , and 𝑘𝑒) have a minor effect on regulating 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 ; (2) Among the properties related to 
TSLs, clearance rate of TSLs (𝑘𝑒_𝐿𝑖𝑝) and the release rate during HT (𝑘𝑟42) are the most 
sensitive parameters, with a 10% increase in  𝑘𝑒_𝐿𝑖𝑝 causing 3.3-6.0% reduction in 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  
while a 10% increase in  𝑘𝑟42  causing 8.0-8.3% increase in  𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 ; (3) Vascular parameters 
also have noticeable influences on 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 , with permeability and surface area product (𝑃𝑆𝑡) 
elevating 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  while blood perfusion rate (𝑤𝑏𝑙𝑜𝑜𝑑) lowering 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 ; (4) The maximum 
efflux transport rate (𝑉𝑚𝑎𝑥_𝑜𝑢𝑡) is another parameter whose effect on 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 cannot be ignored.  
 
The local sensitivity analysis described above has shed new lights on the relative importance 
of and complex interplay among different kinetic steps. This has led to a further detailed 
investigation on how these parameters would influence the time-course of intracellular drug 
concentration and determine the peak intracellular drug concentration over a biologically 
reasonable parameter range under continuous and pulse HT. These are presented in Figure 5 
– Figure 9 and described below. 
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Clearance rate of TSL (𝒌𝒆𝑳𝒊𝒑)  
𝑘𝑒𝐿𝑖𝑝 is varied over a range of 0.1-10 folds of its baseline value, which is sufficient to cover 
the parameter values reported in the literature [17, 18]. Comparisons of temporal profiles of 
𝑐𝑖
𝑇 obtained with the baseline value and the lower and upper bounds are shown in Figure 5(a). 
As 𝑘𝑒𝐿𝑖𝑝 is reduced, 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  increases, and more time is required to reach the peak value. 
Lower 𝑘𝑒𝐿𝑖𝑝 indicates longer circulation time, which helps to maintain sufficient TSL 
concentration in systemic plasma (and tumour plasma) for a longer period. Therefore, longer 
HT exposure (continuous exposure as a limiting case) is favoured for sustained release of 
DOX from TSL, which leads to higher intracellular drug concentration.  
 
𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  is predicted over the same range of 𝑘𝑒𝐿𝑖𝑝under continuous and pulse HT exposure. As 
shown in Figure 5 (b), there are obvious differences between the two heating modes when 
𝑘𝑒𝐿𝑖𝑝 is less than 2 times of its baseline value: higher 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  and more rapid reduction in 
𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  are observed under continuous HT exposure. Beyond this narrow range there is hardly 
any difference between the two heating modes.  
 
Release rate of DOX from TSL during HT (𝒌𝒓𝟒𝟐) 
As a characteristic parameter of TSL, 𝑘𝑟42 depends on the specific composition of liposome. 
A range of  release rates can be found in the literature, and the value chosen in the baseline 
calculation [14] represents a moderate release rate (complete release in ~3 min) which is 
comparable to release kinetics in other computational studies [e.g. 19]. Increasing 𝑘𝑟42up to 
55 folds allows fast release kinetics [20] and ultrafast release kinetics for Thermodox
®
 to be 
simulated. Figure 6 (a) shows changes in intracellular drug concentration with time at 
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different 𝑘𝑟42 under continuous HT. As expected, 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  is higher with fast release kinetics, 
however the relationship is nonlinear and the rate of increase in 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  starts to drop after 
𝑘𝑟42 reaches a certain threshold (around 10 folds of baseline value). The burst release of 
DOX from TSL triggered by HT provides a powerful local source of DOX in tumour plasma 
to drive its downstream transport. Since varying the release rate does not affect the kinetics of 
downstream transport, intracellular drug concentrations reaches its peak at the same time 
regardless of the large variation in 𝑘𝑟42. 
  
Figure 6(b) shows profiles of 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  over a wide range of 𝑘𝑟42 under continuous and 1 h 
pulse heating exposure. It is obvious that 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  is higher under continuous heating than 
under 1 h pulse heating, and the difference widens with the increase in 𝑘𝑟42 until a certain 
value is reached (around 15 folds of baseline). Beyond this point, the difference in 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇   
between the two heating schemes is hardly affected by any further increase in 𝑘𝑟42. These 
results indicate that peak intracellular drug concentration does not increase linearly with the 
release rate of DOX from TSL, and that there is an optimal release rate for a given heating 
scheme. 
 
Blood perfusion rate (𝒘𝒃𝒍𝒐𝒐𝒅) 
The effects of blood perfusion rate, 𝑤𝑏𝑙𝑜𝑜𝑑, on intracellular drug concentration are first 
presented under continuous HT in Figure 7 (a). Compared to the baseline 𝑤𝑏𝑙𝑜𝑜𝑑, low 𝑤𝑏𝑙𝑜𝑜𝑑 
generates overall high intracellular drug concentration, thus a strikingly high 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 , but 
longer time is required to reach the peak intracellular drug concentration. Further results in 
Figure 7 (b) exhibit a distinct trend of 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  as a function of 𝑤𝑏𝑙𝑜𝑜𝑑 under continuous and 
pulse HT exposure. Within a narrow range of very low 𝑤𝑏𝑙𝑜𝑜𝑑, there is a sharp increase in 
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𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 , but beyond this range 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  reduces as 𝑤𝑏𝑙𝑜𝑜𝑑 increases. This is because at high 
perfusion rates, a large amount of bioavailable DOX released upon HT from tumour plasma 
is transported back to systemic plasma, where DOX is cleared rapidly by systemic clearance. 
Such an adverse effect has been demonstrated by a limiting case examined by Gasselhuber et 
al [9], where enhanced intracellular accumulation of DOX was found following vascular 
shutdown induced by a short intense HT exposure after a routine HT exposure. The results 
indicate that high 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  is achieved at relatively low perfusion rates.  
 
Permeability surface area product (𝑷𝑺𝒕) 
Tumour vascular network is highly irregular with dilated and tortuous vessels; as a result, 
vascular permeability and vascular density are heterogeneous even within the same tumour. 
Under the compartmental model setting, a lumped parameter (𝑃𝑆𝑡) - the product of vascular 
permeability of DOX and vascular surface area, is used to describe the transvascular transport 
of DOX. Its effect is further examined over an arbitrarily broad spectrum of values (0.1-10 
folds of the baseline value), to account for differences in tumour vascular permeability and 
vascular density. In a recent study based on a patient-specific liver tumour reconstructed from 
magnetic resonance images [21], vascular density, measured in terms of surface area of blood 
vessels per unit volume of tumour tissue was found to vary between 0.4 and 2.2 folds of its 
baseline value. 
 
The time-course of intracellular drug concentration under continuous HT is displayed at three 
representative values of  𝑃𝑆𝑡 in Figure 8 (a). 𝑃𝑆𝑡 is an important parameter governing the 
transvascular flux of drug: high 𝑃𝑆𝑡 allows more bioavailable DOX to be transported into 
tumour EES, resulting in high intracellular drug concentration in the first hours. On the other 
hand, high 𝑃𝑆𝑡 also causes more intense reverse diffusion of DOX to tumour EES when the 
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concentration gradient is reversed, thus lowering intracellular drug concentration after 
approximately 2 hours following drug administration. 
  
Figure 8 (b) presents 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  over various 𝑃𝑆𝑡 under continuous and pulse HT exposures. The 
results exhibit a saturated effect of 𝑃𝑆𝑡 on 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 , and follow a similar trend to that shown in 
Figure 6 (b). This is explained as follows: 𝑘𝑟42 and 𝑃𝑆𝑡 exert their effects by enhancing the 
amount of DOX available in tumour EES, and when they reach a sufficiently large value, it is 
the kinetics of transmembrane transport that determines the intracellular drug concentration. 
It also implies that improved vascular permeability as a result of heating may enhance 
intracellular drug accumulation in the first 2 hours of HT exposure.  
 
Maximum efflux transport rate (𝑽𝒎𝒂𝒙_𝒐𝒖𝒕) 
𝑉𝑚𝑎𝑥_𝑜𝑢𝑡 is a characteristic parameter governing the kinetics of efflux trans-membrane 
transport. As shown in Figure 9 (a), increasing 𝑉𝑚𝑎𝑥_𝑜𝑢𝑡 reduces intracellular drug 
concentration in general and the time required to reach equilibrium between influx and efflux, 
thus bringing forward the reversal transport across cell membrane. As a result, a large 
fraction of free DOX released upon continuous HT is forced to exit tumour compartment and 
perfuse back to systemic plasma, whereas discontinuity in HT may help to reduce this reverse 
transport. On the other hand, when intracellular drug concentration is down-regulated by a 
reduction in the maximum influx rate (𝑉𝑚𝑎𝑥_𝑖𝑛), continued release of DOX upon constant HT 
can sustain the rise in intracellular drug concentration, which cannot be achieved by pulse 
heating. 
 
From the physiological point of view, over-expression of membrane transporter proteins (e.g. 
p-glycoprotein) results in an increase in 𝑉𝑚𝑎𝑥_𝑜𝑢𝑡, which is responsible for chemotherapeutic 
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drug resistance. For TSL-mediated drug delivery combined with HT, it is worth investigating 
how changes in 𝑉𝑚𝑎𝑥_𝑜𝑢𝑡 may affect 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  under continuous and pulse HT. It can be seen 
from Figure 9 (b) that when 𝑉𝑚𝑎𝑥_𝑜𝑢𝑡 is low (below the baseline value), a much higher 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  
is achieved with continuous HT; when 𝑉𝑚𝑎𝑥_𝑜𝑢𝑡 is above its baseline value, the difference in 
𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  between the two heating schemes is reduced and eventually disappears when relative 
𝑉𝑚𝑎𝑥_𝑜𝑢𝑡 exceeds 2. The results indicate that if the intrinsic kinetics of transmembrane 
transport is altered, the duration of HT can no longer compensate for this effect to achieve a 
desirable 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 . 
 
3.3 Treatment regimen 
TSL infusion time (Td) 
As shown in Figure 10 (a) under continuous HT, the time-course of intracellular drug 
concentration is shifted to the right along the time axis with an increment in Td. With 
prolonged TSL infusion, it takes more time for the transport and accumulation of DOX in the 
tumour intracellular space. Within this context, the time scale of HT exposure is a constraint, 
which may limit the level of intracellular drug concentration. Such an effect is obvious from 
Figure 10 (b) that peak intracellular drug concentration is almost independent of infusion 
time under continuous heating, while it falls continually under 1h pulse HT exposure. Results 
suggest that shorter infusion time is preferred under pulse HT.  
 
Duration of pulse HT exposure  
The effect of heating duration is presented in Figure 11, which shows that increasing HT 
exposure up to approximately 2 h can dramatically increase 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  , but longer than 2 h 
heating results in little change in 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 . This suggests that the duration of pulse HT exposure 
has a saturable effect on peak intracellular concentration. 
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4. Discussion and Conclusion 
TSL in combination with HT have recently emerged as a potential solution to delivering high 
concentrations of chemotherapeutics to targeted tumour sites. The current study focuses on a 
novel release mode of TSL, by which release of encapsulated drug is triggered during transit 
of TSL within tumour plasma in response to HT.  Intravascular triggered release is a 
preferred release mode for TSL delivery of DOX in combination with HT [14], as it can 
provide a boosted local supply of drug at the tumour site and enhance the driving force for 
drug penetration in tumour interstitium [22].  
 
Although a rich body of experimental research has been centred on the design of TSL 
formulation for improved stability and drug release behaviour, there is a lack of 
understanding on the role of these properties in upstream (systemic) and downstream 
(transvascular and intracellular) transport steps in response to HT exposure. We aim to 
address this question systematically by using a multiscale computational model, which 
incorporates descriptions of pharmacokinetics of TSL and free DOX, and drug deposition 
inside the tumour combined with release triggered by HT, on the basis of mechanistic 
understanding of drug delivery. Different from traditional experimental research, the in silico 
experimentations presented here are performed on a well-defined TSL-tumour system with a 
controlled source of variability and heterogeneity to uncover the complex interplay among 
different kinetic steps. 
 
Peak intracellular drug concentration (𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 ) is regarded as the target output; therefore, the 
current study focuses on exploring how the output value is affected by varying input 
parameters including TSL properties, tumour physiological properties and stimulus 
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characteristics (e.g. duration of HT exposure). Our local sensitivity analysis has revealed that 
TSL properties, especially release rate 𝑘𝑟42 during HT, has the greatest influence on 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 . 
Therefore, it is important that TSL should be designed to offer an ideal release rate. An 
interesting finding is that release rate has a saturable effect on 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇   (Figure 6) in that no 
appreciable increase in 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇   could be gained for release rates greater than 0.1018 s
-1
 (20-
fold of the baseline value).  The implication of this finding is that ultra-fast release may not 
be necessary to achieve desirable levels of 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 .  
 
Following a bolus injection of TSL, intracellular drug concentration is found to culminate 
after approximately 2 hours of HT exposure even under continuous HT. When heating 
duration is less than 2 hours, 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  continues to rise with HT exposure time. However, 
prolonging HT exposure beyond 2 hours does not increase 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  further, since equilibrium 
between cellular uptake and outward transport of DOX from cells has been reached. This 
finding is consistent with that of  Gasselhuber et al [9]. Moreover, increasing heating duration 
may not be effective for drug-resistant tumour with overexpression of transmembrane 
transporters (i.e. p-glycoprotein), as heating cannot compensate for the altered kinetics of 
trans-membrane transport due to increased maximum efflux transport rate. Targeted TSL has 
been suggested as a novel strategy to overcome multidrug resistance, e.g. folate-targeted TSL 
developed by Gaber [23]. In addition, injection mode of TSL also affects 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 . 
Comparisons of bolus injection and continuous infusion of TSL suggest that although bolus 
injection offers a higher 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇 , it is also associated with high peak drug concentration in 
systemic plasma which is related to cardiotoxicity [24]. Consequently, continuous infusion 
with longer duration of HT exposure may help to maximise peak intracellular drug 
concentration while keeping a low level of drug concentration in systemic plasma.  
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In conclusion, by employing a multi-compartment model, the current study provides 
numerical results that help to elucidate how peak intracellular drug concentration is regulated 
by the complex interplay among tumour physiology, drug specific properties and treatment 
regimen for TSL-mediated drug delivery combined with intravascular triggered release upon 
local hyperthermia. The mathematical model presented here can be used as a platform to 
accommodate additional complexities and has the flexibility to be tailored for any specific 
tumour-drug systems. 
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Figure captions 
Figure 1. A schematic diagram of the multiple compartment model, incorporating 
pharmacokinetics of liposome (TSLs) and DOX, and DOX transport and deposition in the 
targeting tumour tissue. 
Figure 2. Time-course of drug concentration under continuous HT exposure: (a) in systemic 
and tumour plasma compartments; (b) in tumour compartment. Note that drug concentration 
is based on the volume of the respective compartment.  
Figure 3. Time-course of drug concentration under 1h pulse HT exposure: (a) in systemic and 
tumour plasma compartments; (b) in tumour compartment.   
Figure 4: Results of sensitivity analysis on changes in peak intracellular drug concentration 
(normalised with respect to the peak intracellular drug concentration corresponding to the 
baseline case with parameter values specified in Table 1) with 10% increase in each 
parameter. Positive sensitivity values indicate an increase in peak drug concentration with an 
increase in the tested parameter, whereas negative values predict an opposing effect. Top 
panel: continuous HT; bottom panel: 1h pulse HT.  
Figure 5. (a) Time-course of intracellular drug concentration under continuous HT at various 
clearance rates of TSLs 𝑘𝑒𝐿𝑖𝑝; (b) the effect of varying 𝑘𝑒𝐿𝑖𝑝on peak intracellular drug 
concentration 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  under continuous and 1h pulse HT exposure.  
Figure 6. (a) Time-course of intracellular drug concentration under continuous HT at various 
release rates of TSLs upon HT 𝑘𝑟42. (b) the effect of varying 𝑘𝑟42on peak intracellular drug 
concentration 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  under continuous and 1h pulse HT exposure.  
Figure 7. (a) Time-course of intracellular drug concentration under continuous HT at various 
blood perfusion rates 𝑤𝑏𝑙𝑜𝑜𝑑. (b) the effect of varying 𝑤𝑏𝑙𝑜𝑜𝑑 on peak intracellular drug 
concentration 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  under continuous and 1h pulse HT exposure.  
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Figure 8. (a) Time-course of intracellular drug concentration under continuous HT at various 
permeability surface area products 𝑃𝑆. (b) the effect of varying 𝑃𝑆 on peak intracellular drug 
concentration 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  under continuous and 1h pulse HT exposure.  
Figure 9. (a) Time-course of intracellular drug concentration under continuous HT at various 
maximum efflux transport rates 𝑉𝑚𝑎𝑥_𝑜𝑢𝑡. (b) the effect of varying 𝑉𝑚𝑎𝑥_𝑜𝑢𝑡 on peak 
intracellular drug concentration 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  under continuous and 1h pulse HT exposure.  
Figure 10. (a) Time-course of intracellular drug concentration under continuous HT at 
various infusion duration Td. (b) the effect of varying Td on peak intracellular drug 
concentration 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  under continuous and 1h pulse HT exposure.  
Figure 11. The effect of heating duration on peak intracellular drug concentration 𝑐𝑖,𝑝𝑒𝑎𝑘
𝑇  
following a bolus injection. 
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Table 1. Parameters and baseline values used in the computational model 
Symbol Description Baseline value Reference  
keLip 
Rate constant of TSL 
clearance 
2.228e-4 [1/s] [9] 
ke 
Rate constant of DOX 
clearance 
1.1e-3 [1/s] [9] 
kp 
Transfer constant from 
systemic plasma to tissue 
1.6e-3 [1/s] [9] 
kt 
Transfer constant from tissue 
to systemic plasma 
4.68e-5 [1/s] [9] 
kb 
Binding rate of DOX to tissue 
proteins 
3000 [1/h] [15] 
kd 
Dissociation rate of DOX-
tissue proteins 
1000 [1/h] [15] 
kr37 
Release rate constant from 
TSLs at body temperature 
0.1e-4 [1/s] [14] 
kr42 
Release rate constant from 
TSL during HT (at 42°C) 
50.9e-4 [1/s] [14] 
Ke 
Michaelis constant for 
transmembrane transport 
2.19e-4 [µg/mm
3
] [11] 
Ki 
Michaelis constant for 
transmembrane transport 
1.37 [ng/10
5
 cells] 
 
[11] 
Vmax _in 
Maximum influx rate for 
transmembrane transport 
0.28 
[ng/(10
5
cells·min)] 
 
[11] 
Vmax _out 
Maximum efflux rate for 
transmembrane transport 
0.28 
[ng/(10
5
cells·min)] 
[11] 
 
k1ci 
Rate for passive intracellular 
uptake 
6.33e-4 [1/s] Fit to [9] 
wblood Blood perfusion rate 0.018 [1/s] [9] 
PSt 
Permeability surface area 
product 
7e-3 [1/s] [9] 
Hctt Haematocrit for tumour 
microvasculature 
0.19 [9] 
Vt
B Volume of body tissue 64.47 [L] [9] 
VT Volume of tumour tissue 8.82e-2 [L] Estimated 
vp
T Volume fraction of tumour 0.07452 [9] 
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plasma 
ve
T 
Volume fraction of tumour 
EES 
0.454 [9] 
vi
T 
Volume fraction of 
intracellular space 
0.454 [9] 
Vc Volume of single tumour cell 1e-6 [mm
3
/cell] [11] 
dc 
Tumour cell density per 
tumour volume 
0.454*10
6
 [cells/mm
3
] 
Calculated by 
vi
T Vc⁄  
D  Total dose 49 [mg] 
Calculated at a 
dose of 0.7 
mg/kg in a 70 kg 
human  
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